Molecular profiling of melanoma tumours explains differences in survival after T cell therapy
This article is over 5 years old, and the information may therefore be outdated. The more times metastasised melanoma has mutated and the patient’s immune system has been activated against the tumour – the better the chances of survival after immunotherapy. This is what emerges from a research collaboration between Lund University in Sweden and Herlev university hospital in Denmark. The findings a
